Project Grant R01CA292660
Award Date
3/1/25
Completion Date
2/28/30
Dollars Obligated
$591K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Davis, CA, USA
Similar Awards
The National Cancer Institute (NCI) awarded Virginia Commonwealth University (VCU) a $1,241,427 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate a small molecule inhibitor called PDZ1I for treating advanced, metastatic triple negative breast cancer (TNBC). The project aims to formulate PDZ1I-nano for clinical use, characterize how it stimulates the immune system to suppress tumor growth, define the signaling pathways it targets, and combine it...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Promilead, LLC to evaluate a small-molecule compound, USCYL01, as a potential therapy to enhance the efficacy of immune checkpoint inhibitors (ICIs) for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: 1) assess the toxicity and pharmacokinetic properties of USCYL01 in vitro and in vivo, and 2) test USCYL01 as an adjunct to ICI plus...
This federal Project Grant award, valued at $616,071 and effective from February 2025 to January 2030, was granted by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to The University of Texas Health Science Center at San Antonio (UTHSCSA). The grant supports the development of novel adenosine receptor inverse agonists for the treatment of metastatic triple negative breast cancer (TNBC). TNBC accounts for 15-20% of the approximately 280,000 annual breast cancer diagnoses in...
This Project Grant award of $662,938, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research at Northwestern University to investigate the role of gain-of-function mutant p53 proteins in acute myeloid leukemia (AML). The central objective is to determine how these p53 mutations promote leukemia-initiating cell self-renewal, chromatin accessibility, and 3D chromatin structure, which may contribute to therapy resistance in AML....
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $619,764 to the University of Wisconsin - Madison to develop new combination immunotherapy strategies for treating triple-negative breast cancer (TNBC). The key objectives are to: 1) increase the tumor-selective accumulation of a platelet-mediated immune checkpoint inhibitor (P-aPDL1) by triggering local thrombus formation in TNBC tumors, and 2) modulate the immunosuppressive...
The National Cancer Institute (NCI) awarded a $2,679,816 Project Grant (CFDA 93.396 Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai. The 5-year grant, effective August 1, 2025, will support an integrated research program focused on understanding the role of mutant p53 proteins in tumor progression, invasion, and metastasis. The program consists of four interrelated projects that will use systematic studies, molecular mechanisms, and transcriptional regulation approaches...
The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $571,496 Project Grant to the University of Toledo Health Science Campus Division to conduct research aimed at understanding the mechanisms by which the tumor-intrinsic TAZ expression regulates the tumor microenvironment and immune suppressive cells like myeloid-derived suppressor cells (MDSCs) in triple-negative breast cancer (TNBC). The research project, titled "Dissecting Molecular Mechanisms of Tumor-Induced...
This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), supports research to evaluate the preclinical and clinical activity of DNA methyltransferase (DNMT) inhibitors in combination with chemoimmunotherapy for patients with triple-negative breast cancer (TNBC). The $472,447 award, effective December 1, 2024, focuses on identifying biomarkers, such as DNMT3A expression, that can predict response to these targeted therapies. The proposed...
This Project Grant award from the National Cancer Institute, funded under the Cancer Treatment Research program (CFDA 93.395), is focused on developing peptide drug conjugates to treat triple negative breast cancer (TNBC). The goal is to create novel peptide-based drug delivery systems to improve the efficacy of chemotherapies for this aggressive form of breast cancer. The $530,358 award to Molecular Theranostics LLC will support two key objectives: 1) synthesizing and characterizing a peptide...
This federal Project Grant award of $781,436 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by Cold Spring Harbor Laboratory (CSHL) to optimize anti-N-methyl-D-aspartate receptor (NMDAR) antibodies for the treatment of triple-negative breast cancer (TNBC). The key goals are to: 1) establish an orthotopic mouse model with inducible NMDAR expression in TNBC tumors, 2) screen for NMDAR-reactive antibodies and use cryo-electron microscopy to identify...